{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Microsatellite+Stable+Colorectal+Cancer",
    "query": {
      "condition": "Advanced Microsatellite Stable Colorectal Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Microsatellite+Stable+Colorectal+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T18:02:42.154Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03658772",
      "title": "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Microsatellite Stable Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "grapiprant",
          "type": "DRUG"
        },
        {
          "name": "grapiprant and pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrys Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2018-09-20",
      "completion_date": "2023-03-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03658772"
    },
    {
      "nct_id": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07826390",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SOC (anti-PD-1 + platinum -based chemo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-09-06",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546553"
    },
    {
      "nct_id": "NCT03983993",
      "title": "Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Microsatellite Stable Colorectal Carcinoma",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Microsatellite Stable",
        "RAS Wild Type",
        "Stage IV Colorectal Cancer AJCC v8",
        "MSI-H Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-10-15",
      "completion_date": "2026-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03983993"
    },
    {
      "nct_id": "NCT07079631",
      "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "BNT314",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT327",
          "type": "DRUG"
        },
        {
          "name": "SoC chemotherapy treatment 1",
          "type": "DRUG"
        },
        {
          "name": "SoC chemotherapy treatment 2",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 482,
      "start_date": "2025-07-18",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079631"
    },
    {
      "nct_id": "NCT05919264",
      "title": "FOG-001 in Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Colorectal Cancer",
        "Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Cancer",
        "WNT Pathway",
        "HCC",
        "Desmoid",
        "Microsatellite Stable Colorectal Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "FAP",
        "Endometrial Carcinoma",
        "Prostate Cancer",
        "Microsatellite Instability-High Colorectal Cancer",
        "Adamantinomatous Craniopharyngioma"
      ],
      "interventions": [
        {
          "name": "FOG-001",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX-6",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Trifluridine/tipiracil",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Parabilis Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 595,
      "start_date": "2023-05-23",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05919264"
    },
    {
      "nct_id": "NCT04432857",
      "title": "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple-negative Breast Cancer",
        "NSCLC, Squamous or Non-Squamous",
        "Urothelial Carcinoma of the Bladder",
        "Microsatellite Stable (MSS) Colorectal Cancer (CRC)",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "AN0025",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adlai Nortye Biopharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2020-08-20",
      "completion_date": "2025-01-30",
      "has_results": false,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Houston, Texas • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04432857"
    },
    {
      "nct_id": "NCT05733611",
      "title": "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Metastatic Colorectal Cancer",
        "pMMR",
        "MSS"
      ],
      "interventions": [
        {
          "name": "RP2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RP3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-06-29",
      "completion_date": "2025-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Seattle, Washington",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05733611"
    },
    {
      "nct_id": "NCT02959437",
      "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumors",
        "Advanced Malignancies",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "INCB057643",
          "type": "DRUG"
        },
        {
          "name": "INCB059872",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2017-02-27",
      "completion_date": "2020-03-02",
      "has_results": true,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 8,
      "location_summary": "Duarte, California • La Jolla, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02959437"
    },
    {
      "nct_id": "NCT06444815",
      "title": "A Study of VET3-TGI in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Microsatellite Stable Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Cervical Cancer",
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Melanoma Stage IV",
        "Merkel Cell Carcinoma of Skin",
        "Mesothelioma",
        "Non-small Cell Lung Cancer",
        "Cutaneous Squamous Cell Carcinoma (CSCC)",
        "Urothelial Carcinoma Bladder",
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "VET3-TGI",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "KaliVir Immunotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-09-16",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06444815"
    },
    {
      "nct_id": "NCT04354246",
      "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Ovarian Cancer",
        "Lung Cancer",
        "Colon Cancer",
        "Plasma Cell Neoplasm",
        "Multiple Myeloma",
        "HNSCC",
        "Microsatellite Stable Colorectal Carcinoma",
        "MSS-CRC"
      ],
      "interventions": [
        {
          "name": "Dose escalation: COM902 monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort expansion: COM902 (RDFE) monotherapy.",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).",
          "type": "DRUG"
        },
        {
          "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2020-03-31",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-25T18:02:42.154Z",
      "location_count": 9,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04354246"
    }
  ]
}